Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 78

1.

Co-infection with Staphylococcus aureus after primary influenza virus infection leads to damage of the endothelium in a human alveolus-on-a-chip model.

Deinhardt-Emmer S, Rennert K, Schicke E, Cseresnyés Z, Windolph M, Nietzsche S, Heller R, Siwczak F, Haupt KF, Carlstedt S, Schacke M, Figge MT, Ehrhardt C, Löffler B, Mosig AS.

Biofabrication. 2020 Feb 19;12(2):025012. doi: 10.1088/1758-5090/ab7073.

PMID:
31994489
2.

Staphylococcus aureus Pneumonia: Preceding Influenza Infection Paves the Way for Low-Virulent Strains.

Deinhardt-Emmer S, Haupt KF, Garcia-Moreno M, Geraci J, Forstner C, Pletz M, Ehrhardt C, Löffler B.

Toxins (Basel). 2019 Dec 17;11(12). pii: E734. doi: 10.3390/toxins11120734.

3.

The role of sphingosine-1-phosphate signaling in HSV-1-infected human umbilical vein endothelial cells.

Graber K, Khan F, Glück B, Weigel C, Marzo S, Doshi H, Ehrhardt C, Heller R, Gräler M, Henke A.

Virus Res. 2020 Jan 15;276:197835. doi: 10.1016/j.virusres.2019.197835. Epub 2019 Dec 9.

PMID:
31821843
4.

Type I interferon antagonistic properties of influenza B virus polymerase proteins.

Schreiber A, Liedmann S, Brunotte L, Anhlan D, Ehrhardt C, Ludwig S.

Cell Microbiol. 2020 Feb;22(2):e13143. doi: 10.1111/cmi.13143. Epub 2019 Dec 8.

PMID:
31711273
5.

High Maternal and Low Cord Blood Leptin Are Associated with BMI-SDS Gain in the First Year of Life.

Telschow A, Ferrari N, Deibert C, Flöck A, Merz WM, Gembruch U, Ehrhardt C, Dötsch J, Graf C.

Obes Facts. 2019;12(5):575-585. doi: 10.1159/000502421. Epub 2019 Oct 8.

6.

The annexin A1/FPR2 signaling axis expands alveolar macrophages, limits viral replication, and attenuates pathogenesis in the murine influenza A virus infection model.

Schloer S, Hübel N, Masemann D, Pajonczyk D, Brunotte L, Ehrhardt C, Brandenburg LO, Ludwig S, Gerke V, Rescher U.

FASEB J. 2019 Nov;33(11):12188-12199. doi: 10.1096/fj.201901265R. Epub 2019 Oct 2.

7.

Late activation of the Raf/MEK/ERK pathway is required for translocation of the respiratory syncytial virus F protein to the plasma membrane and efficient viral replication.

Preugschas HF, Hrincius ER, Mewis C, Tran GVQ, Ludwig S, Ehrhardt C.

Cell Microbiol. 2019 Jan;21(1):e12955. doi: 10.1111/cmi.12955. Epub 2018 Oct 23.

PMID:
30223301
8.

In Vitro Models to Study Influenza Virus and Staphylococcus aureus Super-Infection on a Molecular Level.

Bruchhagen C, van Krüchten A, Klemm C, Ludwig S, Ehrhardt C.

Methods Mol Biol. 2018;1836:375-386. doi: 10.1007/978-1-4939-8678-1_18.

PMID:
30151583
9.

Late Endosomal/Lysosomal Cholesterol Accumulation Is a Host Cell-Protective Mechanism Inhibiting Endosomal Escape of Influenza A Virus.

Kühnl A, Musiol A, Heitzig N, Johnson DE, Ehrhardt C, Grewal T, Gerke V, Ludwig S, Rescher U.

mBio. 2018 Jul 24;9(4). pii: e01345-18. doi: 10.1128/mBio.01345-18.

10.

The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression.

Schräder T, Dudek SE, Schreiber A, Ehrhardt C, Planz O, Ludwig S.

Antiviral Res. 2018 Sep;157:80-92. doi: 10.1016/j.antiviral.2018.07.006. Epub 2018 Jul 7.

11.

Metabolic conversion of CI-1040 turns a cellular MEK-inhibitor into an antibacterial compound.

Bruchhagen C, Jarick M, Mewis C, Hertlein T, Niemann S, Ohlsen K, Peters G, Planz O, Ludwig S, Ehrhardt C.

Sci Rep. 2018 Jun 14;8(1):9114. doi: 10.1038/s41598-018-27445-7.

12.

Staphylococcus aureus triggers a shift from influenza virus-induced apoptosis to necrotic cell death.

van Krüchten A, Wilden JJ, Niemann S, Peters G, Löffler B, Ludwig S, Ehrhardt C.

FASEB J. 2018 May;32(5):2779-2793. doi: 10.1096/fj.201701006R. Epub 2018 Jan 11.

PMID:
29401589
13.

Immunomodulatory Nonstructural Proteins of Influenza A Viruses.

Klemm C, Boergeling Y, Ludwig S, Ehrhardt C.

Trends Microbiol. 2018 Jul;26(7):624-636. doi: 10.1016/j.tim.2017.12.006. Epub 2018 Jan 17. Review.

PMID:
29373257
14.

Vemurafenib Limits Influenza A Virus Propagation by Targeting Multiple Signaling Pathways.

Holzberg M, Boergeling Y, Schräder T, Ludwig S, Ehrhardt C.

Front Microbiol. 2017 Dec 14;8:2426. doi: 10.3389/fmicb.2017.02426. eCollection 2017.

15.

Pharmacodynamics, Pharmacokinetics, and Antiviral Activity of BAY 81-8781, a Novel NF-κB Inhibiting Anti-influenza Drug.

Droebner K, Haasbach E, Dudek SE, Scheuch G, Nocker K, Canisius S, Ehrhardt C, von Degenfeld G, Ludwig S, Planz O.

Front Microbiol. 2017 Nov 2;8:2130. doi: 10.3389/fmicb.2017.02130. eCollection 2017.

16.

The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo.

Haasbach E, Müller C, Ehrhardt C, Schreiber A, Pleschka S, Ludwig S, Planz O.

Antiviral Res. 2017 Jun;142:178-184. doi: 10.1016/j.antiviral.2017.03.024. Epub 2017 Apr 2.

17.

Mitogen-activated protein kinases (MAPKs) regulate IL-6 over-production during concomitant influenza virus and Staphylococcus aureus infection.

Klemm C, Bruchhagen C, van Krüchten A, Niemann S, Löffler B, Peters G, Ludwig S, Ehrhardt C.

Sci Rep. 2017 Feb 14;7:42473. doi: 10.1038/srep42473.

18.

Influenza A virus NS1 protein-induced JNK activation and apoptosis are not functionally linked.

Nacken W, Wixler V, Ehrhardt C, Ludwig S.

Cell Microbiol. 2017 Jul;19(7). doi: 10.1111/cmi.12721. Epub 2017 Jan 27.

PMID:
28076660
19.

Influenza A viruses suppress cyclooxygenase-2 expression by affecting its mRNA stability.

Dudek SE, Nitzsche K, Ludwig S, Ehrhardt C.

Sci Rep. 2016 Jun 6;6:27275. doi: 10.1038/srep27275.

20.

Antiviral activity of hydroalcoholic extract from Eupatorium perfoliatum L. against the attachment of influenza A virus.

Derksen A, Kühn J, Hafezi W, Sendker J, Ehrhardt C, Ludwig S, Hensel A.

J Ethnopharmacol. 2016 Jul 21;188:144-52. doi: 10.1016/j.jep.2016.05.016. Epub 2016 May 10.

PMID:
27178637

Supplemental Content

Loading ...
Support Center